Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMA Maintenance Therapy in Favorable Risk AML
NCT06379360Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, decitabine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Jul 2019; status: active, not recruiting.
02
Drugs
azacitidinedecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06379360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06379360.